ML-23613, a competitive inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, was administered to 11 patients with primary hypercholesterolemia. After 4-8 weeks of drug treatment at doses of 50-150 mg/day, serum cholesterol levels were reduced by 11-37% (27% on average) in cases of heterozygous familial hypercholesterolemia and combined hyperlipidemia. A marked reduction in tuberous xanthomas was noticed in a homozygous case of familial hypercholesterolemia, but here the drug was less effective in reducing the serum cholesterol level and a higher dose was required for treatment. Softening of Achilles tendon xanthomas was observed in a case of combined hyperlipidemia. © 1980.
Yamamoto, A., Sudo, H., & Endo, A. (1980). Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis, 35(3), 259–266. https://doi.org/10.1016/0021-9150(80)90124-0